Candidaemia and Central Line-Associated Candidaemia in a Network of Indian ICUs: Impact of COVID-19 Pandemic.
COVID‐19
ICUs
India
bloodstream infections
candidaemia
central line associated candidaemia (CLA‐candidaemia)
healthcare associated infections
surveillance
Journal
Mycoses
ISSN: 1439-0507
Titre abrégé: Mycoses
Pays: Germany
ID NLM: 8805008
Informations de publication
Date de publication:
Sep 2024
Sep 2024
Historique:
revised:
01
08
2024
received:
15
05
2024
accepted:
12
08
2024
medline:
16
9
2024
pubmed:
16
9
2024
entrez:
15
9
2024
Statut:
ppublish
Résumé
Candidaemia is a potentially life-threatening emergency in the intensive care units (ICUs). Surveillance using common protocols in a large network of hospitals would give meaningful estimates of the burden of candidaemia and central line associated candidaemia in low resource settings. We undertook this study to understand the burden and epidemiology of candidaemia in multiple ICUs of India, leveraging the previously established healthcare-associated infections (HAI) surveillance network. Our aim was also to assess the impact that the pandemic of COVID-19 had on the rates and associated mortality of candidaemia. This study included adult patients from 67 Indian ICUs in the AIIMS-HAI surveillance network that conducted BSI surveillance in COVID-19 and non-COVID-19 ICUs during and before the COVID-19 pandemic periods. Hospitals identified healthcare-associated candidaemia and central line associated candidaemia and reported clinical and microbiological data to the network as per established and previously published protocols. A total of 401,601 patient days and 126,051 central line days were reported during the study period. A total of 377 events of candidaemia were recorded. The overall rate of candidaemia in our network was 0.93/1000 patient days. The rate of candidaemia in COVID-19 ICUs (2.52/1000 patient days) was significantly higher than in non-COVID-19 ICUs (1.05/patient days) during the pandemic period. The rate of central line associated candidaemia in COVID-19 ICUs (4.53/1000 central line days) was also significantly higher than in non-COVID-19 ICUs (1.73/1000 central line days) during the pandemic period. Mortality in COVID-19 ICUs associated with candidaemia (61%) was higher than that in non-COVID-19 ICUs (41%). A total of 435 Candida spp. were isolated. C. tropicalis (26.7%) was the most common species. C. auris accounted for 17.5% of all isolates and had a high mortality. Patients in ICUs with COVID-19 infections have a much higher risk of candidaemia, CLAC and its associated mortality. Network level data helps in understanding the true burden of candidaemia and will help in framing infection control policies for the country.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Candidaemia is a potentially life-threatening emergency in the intensive care units (ICUs). Surveillance using common protocols in a large network of hospitals would give meaningful estimates of the burden of candidaemia and central line associated candidaemia in low resource settings. We undertook this study to understand the burden and epidemiology of candidaemia in multiple ICUs of India, leveraging the previously established healthcare-associated infections (HAI) surveillance network. Our aim was also to assess the impact that the pandemic of COVID-19 had on the rates and associated mortality of candidaemia.
METHODS
METHODS
This study included adult patients from 67 Indian ICUs in the AIIMS-HAI surveillance network that conducted BSI surveillance in COVID-19 and non-COVID-19 ICUs during and before the COVID-19 pandemic periods. Hospitals identified healthcare-associated candidaemia and central line associated candidaemia and reported clinical and microbiological data to the network as per established and previously published protocols.
RESULTS
RESULTS
A total of 401,601 patient days and 126,051 central line days were reported during the study period. A total of 377 events of candidaemia were recorded. The overall rate of candidaemia in our network was 0.93/1000 patient days. The rate of candidaemia in COVID-19 ICUs (2.52/1000 patient days) was significantly higher than in non-COVID-19 ICUs (1.05/patient days) during the pandemic period. The rate of central line associated candidaemia in COVID-19 ICUs (4.53/1000 central line days) was also significantly higher than in non-COVID-19 ICUs (1.73/1000 central line days) during the pandemic period. Mortality in COVID-19 ICUs associated with candidaemia (61%) was higher than that in non-COVID-19 ICUs (41%). A total of 435 Candida spp. were isolated. C. tropicalis (26.7%) was the most common species. C. auris accounted for 17.5% of all isolates and had a high mortality.
CONCLUSION
CONCLUSIONS
Patients in ICUs with COVID-19 infections have a much higher risk of candidaemia, CLAC and its associated mortality. Network level data helps in understanding the true burden of candidaemia and will help in framing infection control policies for the country.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13790Subventions
Organisme : CDC HHS
Pays : United States
Organisme : Indian Council of Medical Research
Informations de copyright
© 2024 Wiley‐VCH GmbH. Published by John Wiley & Sons Ltd.
Références
R. M. Ribas, C. Freitas, and P. P. Gontijo Filho, “Nosocomial Bloodstream Infections: Organisms, Risk Factors and Resistant Phenotypes in the Brazilian University Hospital,” Brazilian Journal of Infectious Diseases 11 (2007): 351–354.
A. G. Barnett, K. Page, M. Campbell, et al., “The Increased Risks of Death and Extra Lengths of Hospital and ICU Stay From Hospital‐Acquired Bloodstream Infections: A Case–Control Study,” BMJ Open 3, no. 10 (2013): e003587.
M. Ishikane, K. Hayakawa, S. Kutsuna, N. Takeshita, and N. Ohmagari, “Epidemiology of Blood Stream Infection due to Candida Species in a Tertiary Care Hospital in Japan Over 12 Years: Importance of Peripheral Line‐Associated Candidemia,” PLoS One 11, no. 10 (2016): e0165346.
Y. C. Chen, M. W. Ho, W. C. Chao, and C. C. Chang, “Different Epidemiological Characteristics Between Patients With Non‐Hospital‐Onset and Hospital‐Onset Candidemia: A Retrospective Cohort Study,” Epidemiology and Infection 9, no. 151 (2023): e102, https://doi.org/10.1017/S0950268823000894.
W. Zhang, X. Song, H. Wu, and R. Zheng, “Epidemiology, Species Distribution, and Predictive Factors for Mortality of Candidemia in Adult Surgical Patients,” BMC Infectious Diseases 20, no. 1 (2020): 506, https://doi.org/10.1186/s12879‐020‐05238‐6.
I. Hassan, G. Powell, M. Sidhu, W. M. Hart, and D. W. Denning, “Excess Mortality, Length of Stay and Cost Attributable to Candidaemia,” Journal of Information Security 59 (2009): 360–365.
P. Mathur, P. Malpiedi, K. Walia, et al., “Surveillance of Healthcare‐Associated Bloodstream and Urinary Tract Infections in a National Level Network of Indian Hospitals,” Infection Control and Hospital Epidemiology 41, no. S1 (2020): s398.
H. Alataby, F. Atemnkeng, S. S. Bains, F. M. Kenne, K. Diaz, and J. Nfonoyim, “A COVID‐19 Case Complicated by Candida Dubliniensis and Klebsiella Pneumoniae‐Carbapenem‐Resistant Enterobacteriaceae,” Journal of Medical Cases 11 (2020): 403–406, https://doi.org/10.14740/jmc3588.
A. Gorkem, H. Sav, O. Kaan, and E. Eren, “Coronavirus Disease and Candidemia Infection: A Case Report,” Journal de Mycologie Médicale 31 (2021): 101155, https://doi.org/10.1016/j.mycmed.2021.101155.
B. Awada, W. Alam, M. Chalfoun, G. Araj, and A. R. Bizri, “COVID‐19 and Candida duobushaemulonii Superinfection: A Case Report,” Journal de Mycologie Médicale 31 (2021): 101168, https://doi.org/10.1016/j.mycmed.2021.101168.
O. Katoch, N. Sharad, P. Singh, et al., “High Prevalence of Fungal and NDM‐OXA Producing Gram‐Negative Bacterial Superinfections in the Second Wave of Coronavirus Disease 2019 in India: Experience From a Dedicated Coronavirus Disease 2019 Hospital in North India,” Journal of Global Infectious Diseases 14, no. 4 (2022): 154–161.
B. Kayaaslan, A. Kaya Kalem, D. Asilturk, et al., “Incidence and Risk Factors for COVID‐19 Associated Candidemia (CAC) in ICU Patients,” Mycoses 65, no. 5 (2022): 508–516.
“WHO Fungal Priority Pathogens List to Guide Research, Development and Public Health Action,” 2022, https://www.who.int/publications/i/item/9789240060241.
A. Chowdhary, C. Sharma, and J. F. Meis, “Candida auris: A Rapidly Emerging Cause of Hospital‐Acquired Multidrug‐Resistant Fungal Infections Globally,” PLoS Pathogens 13, no. 5 (2017): e1006290.
P. Mathur, P. Malpiedi, K. Walia, et al., “Health‐Care‐Associated Bloodstream and Urinary Tract Infections in a Network of Hospitals in India: A Multicentre, Hospital‐Based, Prospective Surveillance Study,” Lancet Global Health 10, no. 9 (2022): e1317.
E. Rajni, P. Chaudhary, V. K. Garg, R. Sharma, and M. Malik, “A Complete Clinico‐Epidemiological and Microbiological Profile of Candidemia Cases in a Tertiary‐Care Hospital in Western India,” Antimicrobial Stewardship and Healthcare Epidemiology 2, no. 1 (2022): e37.
B. H. Tan, A. Chakrabarti, R. Y. Li, et al., “Incidence and Species Distribution of Candidaemia in Asia: A Laboratory‐Based Surveillance Study,” Clinical Microbiology and Infection 21, no. 10 (2015): 946–953.
C. D. Russell, C. J. Fairfield, T. M. Drake, et al., “ISARIC4C Investigators: Co‐Infections, Secondary Infections, and Antimicrobial Use in Patients Hospitalised With COVID‐19 During the First Pandemic Wave From the ISARIC WHO CCP‐UK Study: A Multicentre, Prospective Cohort Study,” Lancet Microbe 2 (2021): e354–e365.
B. J. Langford, M. So, S. Raybardhan, et al., “Bacterial Co‐Infection and Secondary Infection in Patients With COVID‐19: A Living Rapid Review and Meta‐Analysis,” Clinical Microbiology and Infection 26 (2020): 1622–1629.
J. W. Baddley, G. R. Thompson, S. C. Chen, et al., “Coronavirus Disease 2019‐Associated Invasive Fungal Infection,” Open Forum Infectious Diseases 8 (2021): ofab510.
S. C. Tan, T. Evans, M. L. Durie, P. J. Secombe, and D. Pilcher, “Mortality Among People Admitted to Australian Intensive Care Units for Reasons Other Than COVID‐19 During the COVID‐19 Pandemic: A Retrospective Cohort Study,” Medical Journal of Australia 218, no. 10 (2023): 467–473, https://doi.org/10.5694/mja2.51933.
A. Dang, R. Thakker, S. Li, E. Hommel, H. B. Mehta, and J. S. Goodwin, “Hospitalizations and Mortality From Non–SARS‐CoV‐2 Causes Among Medicare Beneficiaries at US Hospitals During the SARS‐CoV‐2 Pandemic,” JAMA Network Open 5, no. 3 (2022): e221754, https://doi.org/10.1001/jamanetworkopen.2022.1754.
B. Kayaaslan, F. Eser, A. Kaya Kalem, et al., “Characteristics of Candidemia in COVID‐19 Patients; Increased Incidence, Earlier Occurrence and Higher Mortality Rates Compared to Non‐COVID‐19 Patients,” Mycoses 64 (2021): 1083–1090.
D. Dixit, P. Jen, T. D. Maxwell, S. Smoke, J. A. McCracken, and M. Cardinale‐King, “Risk Factors and Clinical Outcomes of Candidemia Associated With Severe COVID‐19,” Critical Care Explorations Journal 4, no. 9 (2022): e0762, https://doi.org/10.1097/CCE.0000000000000762.
P. G. Pappas, C. A. Kauffman, D. R. Andes, et al., “Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America,” Clinical Infectious Diseases 62 (2016): e1–e50, https://doi.org/10.1093/cid/civ933.
P. Mathur, F. Hasan, P. K. Singh, R. Malhotra, K. Walia, and A. Chowdhary, “Five‐Year Profile of Candidaemia at an Indian Trauma Centre: High Rates of Candida Auris Blood Stream Infections,” Mycoses 61, no. 9 (2018): 674–680.
S. Y. Lin, P. L. Lu, B. H. Tan, et al., “The Epidemiology of Non‐Candida Yeast Isolated From Blood: The Asia Surveillance Study,” Mycoses 62, no. 2 (2019): 112–120.
S. R. Lockhart, K. A. Etienne, S. Vallabhaneni, et al., “Simultaneous Emergence of Multidrug‐Resistant Candida Auris on 3 Continents Confirmed by Whole‐Genome Sequencing and Epidemiological Analyses,” Clinical Infectious Diseases 64, no. 2 (2017): 134–140.
J. Y. Rodriguez, P. Le Pape, O. Lopez, K. Esquea, A. L. Labiosa, and C. Alvarez‐Moreno, “Candida Auris: A Latent Threat to Critically Ill Patients With COVID‐19,” Clinical Infectious Diseases 20 (2020): ciaa1595.
A. Chowdhary, B. Tarai, A. Singh, and A. Sharma, “Multidrug‐Resistant Candida Auris Infections in Critically Ill Coronavirus Disease Patients, India, April–July 2020,” Emerging Infectious Diseases 26, no. 11 (2020): 2694–2696.